Search Results: Treatment + Breast Cancer + Stage 2 or 3 (3 results)
Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/344/study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer
Treatment
Biomarker study for people with early-stage breast cancer
This is a study looking at biomarkers to predict recurrence in people with high-risk, early-stage breast cancer who are planning to undergo chemotherapy. This study will follow patients forward over a period of time to see how well the test cancer predict outcomes.
Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/343/a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer
Treatment
Treatment study for early-stage triple-negative breast cancer
This study is testing whether a shorter course of combined chemotherapy and immunotherapy treatment—without a type of chemotherapy known as an anthracycline—works as well as the standard, longer treatment for people with early-stage triple-negative breast cancer at high risk for recurrence.
A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer + Stage 2 or 3
64 results
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://clinicaltrials.gov/study/NCT05677802)
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
NCT ID: NCT05417867 (https://clinicaltrials.gov/study/NCT05417867)
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
NCT ID: NCT07044310 (https://clinicaltrials.gov/study/NCT07044310)
Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
NCT ID: NCT05130840 (https://clinicaltrials.gov/study/NCT05130840)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
NCT ID: NCT04517838 (https://clinicaltrials.gov/study/NCT04517838)
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05741164 (https://clinicaltrials.gov/study/NCT05741164)
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT ID: NCT06538389 (https://clinicaltrials.gov/study/NCT06538389)
A Study of the TheraBionic P1 Device in Breast Cancer
NCT ID: NCT07218432 (https://clinicaltrials.gov/study/NCT07218432)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06434064 (https://clinicaltrials.gov/study/NCT06434064)
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT ID: NCT06876714 (https://clinicaltrials.gov/study/NCT06876714)
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT ID: NCT06582615 (https://clinicaltrials.gov/study/NCT06582615)
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT ID: NCT01000883 (https://clinicaltrials.gov/study/NCT01000883)
Breast Cancer Survivorship Biorepository
NCT ID: NCT05786664 (https://clinicaltrials.gov/study/NCT05786664)
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT ID: NCT04638751 (https://clinicaltrials.gov/study/NCT04638751)
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
NCT ID: NCT07095114 (https://clinicaltrials.gov/study/NCT07095114)
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT ID: NCT06153836 (https://clinicaltrials.gov/study/NCT06153836)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://clinicaltrials.gov/study/NCT05812807)
National Cancer Institute "Cancer Moonshot Biobank"
NCT ID: NCT04314401 (https://clinicaltrials.gov/study/NCT04314401)
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT ID: NCT04959474 (https://clinicaltrials.gov/study/NCT04959474)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)
Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer
NCT ID: NCT04715958 (https://clinicaltrials.gov/study/NCT04715958)
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
NCT ID: NCT06353997 (https://clinicaltrials.gov/study/NCT06353997)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
Improving Exercise Capacity With a Tailored Physical Activity Intervention
NCT ID: NCT05595577 (https://clinicaltrials.gov/study/NCT05595577)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
NCT ID: NCT06763328 (https://clinicaltrials.gov/study/NCT06763328)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://clinicaltrials.gov/study/NCT04553770)
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
NCT ID: NCT06113016 (https://clinicaltrials.gov/study/NCT06113016)
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
NCT ID: NCT06617455 (https://clinicaltrials.gov/study/NCT06617455)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT ID: NCT02945579 (https://clinicaltrials.gov/study/NCT02945579)
TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
NCT ID: NCT06999798 (https://clinicaltrials.gov/study/NCT06999798)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://clinicaltrials.gov/study/NCT06006806)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://clinicaltrials.gov/study/NCT05607004)
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT ID: NCT00899301 (https://clinicaltrials.gov/study/NCT00899301)
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
NCT ID: NCT06727773 (https://clinicaltrials.gov/study/NCT06727773)
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
NCT ID: NCT03941756 (https://clinicaltrials.gov/study/NCT03941756)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://clinicaltrials.gov/study/NCT06058377)
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
NCT ID: NCT06630325 (https://clinicaltrials.gov/study/NCT06630325)
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108 (https://clinicaltrials.gov/study/NCT05919108)
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://clinicaltrials.gov/study/NCT05595499)
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT ID: NCT05710328 (https://clinicaltrials.gov/study/NCT05710328)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://clinicaltrials.gov/study/NCT05673200)
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://clinicaltrials.gov/study/NCT06275126)
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT ID: NCT05183828 (https://clinicaltrials.gov/study/NCT05183828)
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
NCT ID: NCT07016399 (https://clinicaltrials.gov/study/NCT07016399)
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
NCT ID: NCT06954831 (https://clinicaltrials.gov/study/NCT06954831)
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT ID: NCT06635980 (https://clinicaltrials.gov/study/NCT06635980)
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT ID: NCT07158021 (https://clinicaltrials.gov/study/NCT07158021)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://clinicaltrials.gov/study/NCT05288777)
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
NCT ID: NCT06671912 (https://clinicaltrials.gov/study/NCT06671912)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.